Skip to Content
MilliporeSigma
All Photos(1)

Documents

SML1668

Sigma-Aldrich

Tipifarnib

≥98% (HPLC)

Synonym(s):

(R)-(+)-R 115777, 6-[(R)-Amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone, R115777

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C27H22Cl2N4O
CAS Number:
Molecular Weight:
489.40
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D 17 to 24°, c = 1 in methanol

color

white to beige

solubility

DMSO: 10 mg/mL, clear

Storage temp.

−20°C

SMILES string

CN(C1=CC=C([C@](C2=CN=CN2C)(N)C3=CC=C(Cl)C=C3)C=C1C(C4=CC=CC(Cl)=C4)=C5)C5=O

InChI

1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1

Inchi Key

PLHJCIYEEKOWNM-HHHXNRCGSA-N

General description

Pre-clinical studies show that tipifarnib has antiproliferative effects on pancreatic cancer cell lines at clinically relevant concentrations (concentration that inhibits 50% growth [IC50] from 9.5 to 500 nmol/L). It also exhibits marked growth retardation and antiangiogenic effects in a pancreatic cancer xenograft model.

Biochem/physiol Actions

Tipifarnib (R115777) is an orally active and potent farnesyltransferase (FTase) inhibitor that exhibits potent anti-tumorigenic effects. Tipifarnib mechanism of action is not fully understand.

Pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Van E C, et al.
Journal of Clinical Oncology, 22(8), 1430-1438 (2004)
Madeleine Dorsch et al.
Cell reports, 37(8), 110056-110056 (2021-11-25)
Statins are among the most commonly prescribed drugs, and around every fourth person above the age of 40 is on statin medication. Therefore, it is of utmost clinical importance to understand the effect of statins on cancer cell plasticity and

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service